English
Home > Products > 73227-23-3

China 73227-23-3 Factory

Our firm sticks to the basic principle of "Quality is the life of your company, and status will be the soul of it" for 73227-23-3,CAS NO 73227-23-3,NEODYMIUM 2-ETHYLHEXANOATE, Our mission should be to assist you build long-lasting interactions with the purchasers as a result of the ability of promotional solutions.
73227-23-3, We have been in operation for more than 10 years. We have been dedicated to quality products and solutions and consumer support. We currently own 27 product utility and design patents. We invite you to visit our company for a personalized tour and advanced business guidance.

Related Products

Hot Products

  • 1H-Pyrrolo[2,3-b]pyridin-5-ol

    1H-Pyrrolo[2,3-b]pyridin-5-ol

    Product Name:1H-Pyrrolo[2,3-b]pyridin-5-ol
    Molecular Formula:C7H6N2O
    Molecular Weight:134.14
    CAS Registry Number:98549-88-3
  • lfosfamide

    lfosfamide

    Product Name:lfosfamide
    Molecular Formula:C7H15Cl2N2O2P
    Molecular Weight:261.09
    CAS Registry Number:3778-73-2
  • 3-Amino-1,2,3,4-tetrahydrocarbazol

    3-Amino-1,2,3,4-tetrahydrocarbazol

    Product Name:3-Amino-1,2,3,4-tetrahydrocarbazol
    Molecular Formula:C12H14N2
    Molecular Weight:186.25
    CAS Registry Number:61894-99-3
  • 3-Tolylboronic acid

    3-Tolylboronic acid

    Product Name:3-Tolylboronic acid
    Molecular Formula:C7H9BO2
    Molecular Weight:135.96
    CAS Registry Number:17933-03-8
  • Irinotecan

    Irinotecan

    Product Name:Irinotecan
    Molecular Formula:C33H38N4O6
    Molecular Weight;586.68
    CAS Registry Number;97682-44-5
  • Methyl 4-(acetylaMino)-3-broMo-5-chloro-2-hydroxybenzoate

    Methyl 4-(acetylaMino)-3-broMo-5-chloro-2-hydroxybenzoate

    Product Name:Methyl 4-(acetylaMino)-3-broMo-5-chloro-2-hydroxybenzoate
    Molecular Formula:C10H9BrClNO4
    Molecular Weight:322.54
    CAS Registry Number:232941-14-9
  • Related Blog
  • Reviews

  • Why API manufacturing companies almostly in China?

    In the chemical API industry, developed countries such as the United States and Europe occupy a dominant position in the field of patented APIs with high added value by virtue of their advantages in research and development, production technology, and intellectual property protection...

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products can be produced in ordinary chemical plants without obtaining a pharmaceutical production license. As long as the technical indicators meet certain level requirements, they can be used to participate in the synthesis and production of drugs.

  • How to find the best China API manufacturer?

    Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs. The active ingredient (AI) is the substance or substances that are biologically active within the drug and is the specific component responsible for the desired effect it has on the individual taking it.

  • What are pharmaceutical intermediates?

    Pharmaceutical intermediates are fine chemical products in the production process from pharmaceutical chemical raw materials to bulk drugs or drugs. The synthesis of chemical drugs depends on high-quality pharmaceutical intermediates. This chemical, which does not require a drug production license, can be produced in ordinary chemical plants and can be used in the synthesis of drugs as long as it reaches certain grades.

  • CAS No. 144689-24-7 Olmesartan Introduction

    Olmesartan is an angiotensin II receptor blocker, widely used for the treatment of hypertension. The Renin-Angiotensin-Aldosterone System (RAAS) plays an importent role in the development and progression of many diseases such as hypertension...

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Related Search

CAS NO 73227-23-3

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept